Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features

C Rosty; JP Young; MD Walsh; M Clendenning; RJ Walters; S Pearson; E Pavluk; B Nagler; D Pakenas; JR Jass; MA Jenkins; AK Win; MC Southey; S Parry; JL Hopper; GG Giles; E Williamson; DR English; DD Buchanan

Journal article

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features

C Rosty, JP Young, MD Walsh, M Clendenning, RJ Walters, S Pearson, E Pavluk, B Nagler, D Pakenas, JR Jass, MA Jenkins, AK Win, MC Southey, S Parry, JL Hopper, GG Giles, E Williamson, DR English, DD Buchanan

Modern Pathology | NATURE PUBLISHING GROUP | Published : 2013

DOI: 10.1038/modpathol.2012.240

Abstract

KRAS-mutated carcinomas comprise 35-40% of all colorectal carcinomas but little is known about their characteristics. The aim of this study was to examine the pathological and molecular features of KRAS-mutated colorectal carcinomas and to compare them with other carcinoma subgroups. KRAS mutation testing was performed in 776 incident tumors from the Melbourne Collaborative Cohort Study. O 6 -methylguanine DNA methyltransferase (MGMT) status was assessed using both immunohistochemistry and MethyLight techniques. Microsatellite instability (MSI) phenotype and BRAF V600E mutation status were derived from earlier studies. Mutation in KRAS codon 12 or codon 13 was present in 28% of colorectal ca..

View full abstract

University of Melbourne Researchers

Mark Clendenning Author

Mark Jenkins Author

Aung Ko Win Author

Melissa Southey Author

Related Projects (2)

COMPREHENISVE MODEL FOR COLORECTAL CANCER RISK

I am a genetic epidemiologist focused on bowel cancer risk. I will develop a comprehensive model to estimate individual cancer risk by study..

Do different types of bowel cancer have different risk factors?

Colorectal cancer is Australia's most common cancer. It actually has several subtypes that probably have different causes and which may resp..

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

We thank all study participants of the Melbourne Collaborative Cohort Study (NHMRC 509348) for their contributions to this project. We also acknowledge the contributions of Charmaine Smith, Lisa Oates and Sonia Terre'Blanche from the Cancer Council Victoria for their assistance with tissue block acquisition. This work was supported by the National Health and Medical Research Council and Cancer Council Victoria. During this work, JPY was a Cancer Council Queensland Senior Research Fellow. CR is a Jass Pathology Fellow. MAJ is a NHMRC Senior Research Fellow and JLH is a NHMRC Australia Fellow.